BeyondSpring (BYSI) Corporate Presentation summary

Investment highlights and strategic positioning

• Plinabulin demonstrated favorable safety and anti-cancer efficacy, with over 700 cancer patients treated and positive Phase 3 results in 2L/3L NSCLC, showing durable overall survival benefits and reduced chemotherapy-associated adverse events.

• Promising efficacy observed in triple IO combinations for patients who failed prior immunotherapies, with multiple Phase 1/2 studies expected to inform pivotal trials in 2025.

• SEED Therapeutics, a subsidiary, has a novel targeted protein degradation (TPD) platform with 9 disclosed pipeline assets, including one expected to enter first human dose in 2025, and has secured investments and collaborations with Eli Lilly and Eisai.

• Strong global patent protection for both Plinabulin and SEED's TPD platform, with patents granted or allowed to 2039 in over 40 jurisdictions.

• Sale of a portion of SEED equity raised $35.4M in non-dilutive financing, supporting late-stage clinical trials for Plinabulin and maintaining a 14.4% stake in SEED.

Plinabulin clinical development and efficacy

• Plinabulin, a first-in-class late-stage clinical asset, induces innate and adaptive immunity via dendritic cell maturation, enhancing antigen presentation and T cell activation.

• Demonstrated significant improvement in overall survival, progression-free survival, and objective response rate in 2L/3L NSCLC patients when combined with docetaxel, with a hazard ratio for OS of 0.82 and doubling of 2- and 3-year OS rates.

• Plinabulin significantly reduced grade 4 neutropenia (>80% reduction) and allowed for increased treatment cycles, improving both safety and efficacy.

• Clinical benefit observed across multiple cancers, including head and neck cancer and Hodgkin's lymphoma, with broad applicability in combination regimens.

• Well-tolerated safety profile, with manageable side effects and significant reduction in chemotherapy-induced neutropenia.

Plinabulin in immunotherapy-resistant cancers

• Triple IO combination (Plinabulin + PD-1/PD-L1 + chemo/radiation) showed >50% disease control rate in IO-failed patients, with durable responses in heavily pre-treated cases.

• Early immune activation and dendritic cell maturation observed in responding patients, supporting the mechanism of action.

• Phase 2 IIT 303 study in metastatic NSCLC post-PD-1/PD-L1 progression showed an ORR of 21.1%, mPFS of 8.6 months, and DCR of 89.3%, outperforming historical controls.

• Combination regimen was well tolerated, with manageable grade 3+ adverse events.